Last €12.18 EUR
Change Today +0.17 / 1.42%
Volume 20.8K
IBAB On Other Exchanges
Symbol
Exchange
Stuttgart
EN Brussels
OTC US
As of 11:35 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ion beam applications (IBAB) Snapshot

Open
€11.92
Previous Close
€12.01
Day High
€12.31
Day Low
€11.83
52 Week High
07/4/14 - €12.46
52 Week Low
07/24/13 - €5.67
Market Cap
343.3M
Average Volume 10 Days
23.6K
EPS TTM
€-0.13
Shares Outstanding
28.2M
EX-Date
05/14/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ION BEAM APPLICATIONS (IBAB)

Related News

No related news articles were found.

ion beam applications (IBAB) Related Businessweek News

No Related Businessweek News Found

ion beam applications (IBAB) Details

Ion Beam Applications SA operates as a cancer diagnostics and treatment equipment company in Belgium, the United States, and internationally. The company develops, manufactures, and supports medical devices and software solutions for cancer treatment by proton beam therapy. It operates in two segments, Proton therapy and Particle accelerators, and Dosimetry. The Proton therapy and Particle accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of Positron Emission Tomography or Single Photon Emission Computed Tomography radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment offers measurement and quality assurance instruments for radiotherapy and medical imaging to enable the healthcare professionals to verify that equipment administers the planned dose to the targeted area. The company was founded in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

1,037 Employees
Last Reported Date: 04/12/14
Founded in 1986

ion beam applications (IBAB) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: €615.0K
Compensation as of Fiscal Year 2013.

ion beam applications (IBAB) Key Developments

Ion Beam Applications S.A. Signs Contract to Install 70 Mev Cyclotron for to the Production of Radiopharmaceuticals in Russia

Ion Beam Applications S.A. announced it has signed a contract with a significant upfront payment with the Centre for Development of Nuclear Medicine in Moscow, Russia, for the installation of its Cyclone®70. The installation of the system is worth between EUR 12 and 15 million to IBA. This 70 MeV Cyclotron will be dedicated to the production of new generation medical isotopes used mainly in the diagnosis of severe diseases.

Ion Beam Applications SA Signs Second Proteus®ONE Contract in Japan

Ion Beam Applications SA announced that it has signed a second contract with a significant upfront payment for the installation of its compact single- room proton therapy system Proteus®ONE in Japan, subject to obtaining market authorization. The typical end-user price for Proteus®ONE is between EUR 20 and 25 million, depending on exact scope of supply. The center, which will be installed on the Hokkaido island in the North of Japan, is expected to treat its first patient in 2017.

Ion Beam Applications, S.A. Reports Consolidated Revenue Results for the First Quarter Ended March 31, 2014; Reiterates Earnings Guidance for the Year 2014

Ion Beam Applications, S.A. reported consolidated revenue results for the first quarter ended March 31, 2014. For the quarter, the company reported revenues of EUR 46.3 million, up 4% compared to the same period in 2013. A 19% growth in Dosimetry and 6% growth in Other Accelerators year on year compensated for a temporarily slower conversion of the Proton Therapy order book. The company reiterates its guidance; the company anticipates growth in Group revenues in 2014 of 5% to 10% in line with medium term guidance. Service revenues are expected to grow from EUR 43 million in 2013 to approximately EUR 61 million in 2014. The Company expects to reach the targeted 10% operating margin for the full year 2014, supported by the productivity and efficiency initiatives rolled out across the organization and the growing importance of services to the installed base. The company expects to report positive net profits during 2014. Net debt is expected to continue to reduce significantly during 2014 and be close to zero by the end of the year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBAB:BB €12.18 EUR +0.17

IBAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $38.31 USD -0.21
Analogic Corp $75.94 USD -0.46
Balchem Corp $49.99 USD -0.71
Nordion Inc C$13.90 CAD +0.65
Quidel Corp $21.52 USD +0.33
View Industry Companies
 

Industry Analysis

IBAB

Industry Average

Valuation IBAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ION BEAM APPLICATIONS, please visit www.iba-worldwide.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.